Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/12/2024 | $19.50 → $21.50 | Mkt Perform → Outperform | Keefe Bruyette |
| 1/16/2024 | $17.00 → $17.50 | Buy → Neutral | Compass Point |
| 11/21/2023 | $17.00 | Neutral | UBS |
| 8/30/2023 | $17.50 | Neutral → Buy | Compass Point |
| 8/4/2023 | $13.50 → $17.00 | Underperform → Mkt Perform | Keefe Bruyette |
| 4/6/2023 | $16.00 | Neutral → Overweight | Piper Sandler |
| 3/13/2023 | $14.50 → $10.50 | Mkt Perform → Underperform | Keefe Bruyette |
| 7/29/2022 | Outperform → Perform | Oppenheimer |
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
Keefe Bruyette upgraded Hercules Capital from Mkt Perform to Outperform and set a new price target of $21.50 from $19.50 previously
Compass Point downgraded Hercules Capital from Buy to Neutral and set a new price target of $17.50 from $17.00 previously
UBS initiated coverage of Hercules Capital with a rating of Neutral and set a new price target of $17.00
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
40-17G - Hercules Capital, Inc. (0001280784) (Filer)
8-K - Hercules Capital, Inc. (0001280784) (Filer)
N-2ASR - Hercules Capital, Inc. (0001280784) (Filer)
Record Q3 2024 Total Investment Income of $125.2 Million, an Increase of 7.3% Year-over-Year Q3 2024 Net Investment Income "NII" of $83.2 Million, or $0.51 per Share, an Increase of 8.3% Year-over-Year Q3 2024 NII Provides 128% Coverage of the Base Cash Distribution Q3 2024 Total Gross Debt and Equity Commitments of $430.7 Million Q3 2024 Total Gross Fundings of $272.0 Million Conservative Balance Sheet Management with Net GAAP Leverage of 92.5% and Net Regulatory Leverage of 83.0% Undistributed Earnings Spillover of $152.1 Million, or $0.94(1) per Ending Shares Outstanding Approximately $4.6 Billion of Assets Under Management, an Increase of 10.9% Year-over-Year(2) Hercules Capital
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its third quarter 2024 financial results conference call for Wednesday, October 30, 2024, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will release its financial results after market close that same day. To participate via telephone, please register here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access
Q2 2024 Total Gross Debt and Equity Commitments of $686.5 Million Record Q2 2024 Total Gross Fundings of $461.5 Million, an Increase of 28.7% Year-over-Year Record Q2 2024 Total Investment Income of $125.0 Million, an Increase of 7.5% Year-over-Year Q2 2024 Net Investment Income "NII" of $82.4 Million, or $0.51 per Share, an Increase of 8.8% Year-over-Year Q2 2024 NII Provides 128% Coverage of the Base Cash Distribution Conservative Balance Sheet Management with Net GAAP Leverage of 93.3% and Net Regulatory Leverage of 83.9% Undistributed Earnings Spillover of $145.0 Million, or $0.89(1) per Ending Shares Outstanding Approximately $4.6 Billion of Assets Under Management, an In
SAUSALITO, Calif., Nov. 29, 2023 /PRNewswire/ -- Revelation Partners, a healthcare investment firm with over $1.5 billion of capital under management, announced today the addition of Andrew Olson as Partner, Chief Financial Officer and Chief Operating Officer. Mr. Olson has an extensive background in the venture capital and funds management industry. His addition to the team will enhance the firm's technical expertise, support the differentiated investment model, and strengthen the firm's ongoing foundation. As the firm's new Chief Financial Officer and Chief Operating Officer
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Nikos Theodosopoulos was appointed to serve as an independent member of its board of directors, effective September 21, 2023. Mr. Theodosopoulos is an experienced corporate executive and board director with more than 38 years in senior management roles in both the financial services and technology industries. Mr. Theodosopoulos will serve on the Company's Audit Committee. "Nikos' combined experienc
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that DeAnne Aguirre was appointed to serve as an independent member of its board of directors, effective June 23, 2022. Ms. Aguirre is an experienced corporate executive and Board Director with more than 30 years in senior leadership managing large and complex domestic and international business units. Ms. Aguirre will serve on the Nominating and Corporate Governance Committee. "As we continue to expand o
INDIANAPOLIS, Dec. 19, 2024 /PRNewswire/ -- Remodel Health, the #1 Individual Coverage Health Reimbursement Arrangement (ICHRA) provider for brokers, today announced it has raised more than $100 million from Oak HC/FT and Hercules Capital, Inc. (NYSE:HTGC) in growth funding. Remodel Health has raised more than $100 million from Oak HC/FT and Hercules Capital, Inc. in growth funding.Remodel offers an end-to-end, white-labeled tech platform that supports employers and employees with everything they need to launch and access their ICHRA plans, including plan creation and adminis
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has renewed and upsized its existing $225.0 million credit facility with Sumitomo Mitsui Banking Corporation ("SMBC") with an upsized credit facility under which Synovus Bank, Customers Bank and Apple Bank, together with SMBC, have committed a total of $300.0 million in credit capacity subject to borrowing base, leverage and other restrictions. The renewed credit facility also includes an uncommitte
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE:HTGC) for up to $50 million. "Alector is in a strong cash position with more than $457 million in cash and investments. This credit facility further enhances our financial strength and provides the Company with increased strategic and operational flexibility," said Marc Grasso, M.D., Chief Financial Officer of Alector. "We anticipate transformational data from both the AL002 INVOKE-2 Phase 2 trial and the latozinemab INFRO
SC 13G - Hercules Capital, Inc. (0001280784) (Subject)
SC 13G/A - Hercules Capital, Inc. (0001280784) (Filed by)
SC 13G - Hercules Capital, Inc. (0001280784) (Filed by)